ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs

Understanding how SARS-CoV-2 gains initial entry into the human body is a key step towards the development of prophylaxes and therapeutics for COVID-19. Here, the authors show that ACE2, the receptor for SARS-CoV-2, is abundantly expressed in the motile cilia of the human nasal and respiratory tract...

Full description

Bibliographic Details
Main Authors: Ivan T. Lee, Tsuguhisa Nakayama, Chien-Ting Wu, Yury Goltsev, Sizun Jiang, Phillip A. Gall, Chun-Kang Liao, Liang-Chun Shih, Christian M. Schürch, David R. McIlwain, Pauline Chu, Nicole A. Borchard, David Zarabanda, Sachi S. Dholakia, Angela Yang, Dayoung Kim, Han Chen, Tomoharu Kanie, Chia-Der Lin, Ming-Hsui Tsai, Katie M. Phillips, Raymond Kim, Jonathan B. Overdevest, Matthew A. Tyler, Carol H. Yan, Chih-Feng Lin, Yi-Tsen Lin, Da-Tian Bau, Gregory J. Tsay, Zara M. Patel, Yung-An Tsou, Alexandar Tzankov, Matthias S. Matter, Chih-Jaan Tai, Te-Huei Yeh, Peter H. Hwang, Garry P. Nolan, Jayakar V. Nayak, Peter K. Jackson
Format: Article
Language:English
Published: Nature Portfolio 2020-10-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-020-19145-6